|
|
|
|
|
| April 15 ,
2010 | ISSUE NUMBER 144 VOL 8 |
Regulation
Discussions About Drug User-Fees
The Prescription Drug User Fee Act will expire in 2012 and FDA is working hard to renegotiate the act before that end date. The contenders: in one corner, the pharma industry; in the other, the general public and consumers—and just about everyone has an opinion about what needs to be changed.
FDA
Feds End Use of Seven Inhalers
In an effort to curb the amount of chlorofluorocarbons entering the atmosphere, FDA will phase out several CFC-emitting asthma inhalers.
R&D
Clinical Trial Diversity and You
Lilly’s aggressive approach to shrinking the racial gap in drug trials might indicate big changes for the drugmaking process.
Media
Sixth Annual Press Audit
Pricing, promotion, and the unfinished story of healthcare reform dominated the news last year.
Call for Nominations
Pharmaceutical Executive¹s Emerging Pharma Leadership Award
The pharma industry is facing some tough times‹and the old way of doing things just won¹t work. So just who are the new leaders steering the industry though its most difficult challenges? Which executives are revamping the industry‹through pure innovation‹to remake it for the 21st century?
These emerging leaders are vital to the future of the industry, and you can help ensure that they get the recognition they deserve. Fill out your nomination today! |
|
 |
| 
|
 Sangamo BioSciences added Stephen Dilly to its board. // Bristol-Myers Squibb made Charles Bancroft its permanent CFO, filling the spot left open by Jean-Marc Huet.
// Novovax elected James Young to its board.
// Peter Ciano was upped to VP of corporate development at Tris Pharma.
//Advanced Life Sciences elected John Flavin, Richard Reck, and Rosalie Sagraves to its board.
// Ardea Biosciences hired Stephen Davis as EVP and COO.
// CeQur appointed Robert O’Holla as EVP of regulatory affairs.
// K-V Pharmaceutical hired Stephen Stamp as its new CFO and treasurer. He had been COO and CFO at Xanodyne. // After being acquired by an investment group, Arobor Pharmaceuticals named Jason Wild chairman of the board and Edward Schutter CEO and a member of the board.
// |
|
|
|
 |
|
 |
|
 |
| If you plan to enter emerging markets over the next 3 years, what will be your primary entry strategy? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
